
ACE inhibitors cut all-cause mortality 10% in RCT meta-analysis; ARBs showed none
A summary of the evidence on ACE inhibitors versus ARBs for all-cause mortality. RCT meta-analyses favor ACE inhibitors, while observational and head-to-head data are mixed or neutral, so the question is not settled. ARBs are better tolerated (less cough and angioedema).



